General Biologicals Unveils CTC Cancer Detection Products and Automated Molecular System

GBC is officially entering the U.S. market with its award-winning brand, featuring a highly competitive niche In Vitro Diagnostic (IVD) device and assay.

GBC's pair of CTC detection systems, recognized globally as cutting-edge devices, offer rapid, accessible, and affordable diagnostic solutions for early detection, treatment validation, and therapy monitoring. The CellBio platform employs GBC's proprietary iFiltration technology to provide positive control and guarantee filtration accuracy, leading to Taiwan's first standardized CTC system. This patented technology won the 2022 Taiwan National Innovation Award.

The CellBio system offers several advantages including high specificity, sensitivity, and cancer capture rate from 7.5-mL blood samples, delivering results within 90 minutes. The system is applicable to cancer screening, diagnosis, monitoring, and prognosis; it offers optimal treatment and enhances patients' quality of life. During the non-invasive sampling process, the number of CTCs in the blood can be fully monitored, and the system's capture rate of over 90% of cancer cells surpasses the industry standard. The CellBio FX10 accommodates 10 samples simultaneously and features a full-color touch screen, while the CellBio a2000 can handle two samples at a time in compact labs. With over 8,000 samples already processed, GBC has demonstrated strong efficacy.

Alongside CTC systems, GBC is launching its automated all-in-one molecular system, GB RealQuant AIO. This integrated instrument combines extraction, amplification, and detection, delivering fast and reliable results within two hours with high flexibility. The system is compatible with all GB RealQuant HBV, HCV, and HPV Kits.

“CellBio focuses on the detection, monitoring and treatment of cancer metastasis. The goal of GBC is to revolutionize the detection and treatment of cancer through its unique CTC technology and complementary therapeutics platform CellBio,” said Frank Lin, the President of GBC. “More than 10 million patients die from cancer each year and more than 90 percent of the deaths are attributed to metastasis. Currently, there are no approved therapies that specifically target the metastatic process. Targeting CTCs with novel therapeutics could likely have a significant impact on cancer metastases and patient outcome.”

Related Links:
GBC